Last 12 months
Inside the activity.
0 purchase rows · 16 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 02, 2022 Filed May 4, 2022 21:53 UTC |
DONNELLY SCOTT CDirector
|
GrantOrdinary Shares | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013284 · form4.xml · nonDerivative · entry 1 DONNELLY SCOTT C · CIK 0001233158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,124 Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:40 UTC |
ARNOLD CRAIGDirector
|
GrantOrdinary Shares | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013263 · form4.xml · nonDerivative · entry 1 ARNOLD CRAIG · CIK 0001188578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,681 Read SEC document |
| May 02, 2022 Filed May 4, 2022 22:08 UTC |
HOGAN RANDALL JDirector
|
GrantOrdinary Shares | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013306 · form4.xml · nonDerivative · entry 1 HOGAN RANDALL J · CIK 0001189049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,409 Read SEC document |
| May 02, 2022 Filed May 4, 2022 22:50 UTC |
ANDERSON RICHARD HDirector
|
GrantOrdinary Shares | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013328 · form4.xml · nonDerivative · entry 1 ANDERSON RICHARD H · CIK 0001200334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,444 Read SEC document |
| May 02, 2022 Filed May 4, 2022 22:54 UTC |
Goldsmith Andrea JoDirector
|
GrantOrdinary Shares | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013330 · form4.xml · nonDerivative · entry 1 Goldsmith Andrea Jo · CIK 0001730514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,712 Read SEC document |
| May 02, 2022 Filed May 4, 2022 22:23 UTC |
NABEL ELIZABETH GDirector
|
GrantOrdinary Shares | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013317 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,080 Read SEC document |
| March 18, 2022 Filed Mar 21, 2022 23:34 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
SaleOrdinary Shares | 682 | $110.00 | $75,020.00 |
DisclosureSEC source: 0001127602-22-010109 · form4.xml · nonDerivative · entry 1 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,946 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: This balance increased by 182 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 17:46 UTC |
Surface Carol ASVP, Chief HR Officer
|
SaleOrdinary Shares | 6,000 | $105.30 | $631,800.00 |
DisclosureSEC source: 0001127602-22-009166 · form4.xml · nonDerivative · entry 1 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,502 F1 · balance_after: This balance increased by 175 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:13 UTC |
Kirk Jennifer MChief Accounting Officer
|
Tax withholdingOrdinary Shares | 636 | $103.59 | $65,883.24 |
DisclosureSEC source: 0001127602-22-003003 · form4.xml · nonDerivative · entry 1 Kirk Jennifer M · CIK 0001613343 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,934 F1 · shares: The reported transaction involved the withholding of 636 shares of stock issuable upon the vesting of certain restricted stock units. F2 · balance_after: This balance increased by 183 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 18:25 UTC |
Fong Ivan KEVP GENERAL COUNSEL & SECR
|
GrantPerformance Share Units · Derivative | 21,238 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003243 · form4.xml · derivative · entry 6 Fong Ivan K · CIK 0001342238 · EVP GENERAL COUNSEL & SECR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,238 Underlying: Performance Share Units · 21,238 shares Expires not disclosed F4 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F8 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 21,238 shares will be issued. The actual number of shares to be issued could range from a low of 4,248 at minimum performance to a high of 42,476 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F6 · derivative.exercise_date: Vests on August 2, 2024. F6 · derivative.expiration_date: Vests on August 2, 2024. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 18:25 UTC |
Fong Ivan KEVP GENERAL COUNSEL & SECR
|
GrantStock Option (Right to Buy) · Derivative | 145,852 | $103.59 Strike: $103.59 | $15,108,808.68 |
DisclosureSEC source: 0001127602-22-003243 · form4.xml · derivative · entry 5 Fong Ivan K · CIK 0001342238 · EVP GENERAL COUNSEL & SECR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,852 Underlying: Ordinary Shares · 145,852 shares Expires 2032-02-01 F7 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 18:25 UTC |
Fong Ivan KEVP GENERAL COUNSEL & SECR
|
GrantPerformance Share Units · Derivative | 15,591 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003243 · form4.xml · derivative · entry 4 Fong Ivan K · CIK 0001342238 · EVP GENERAL COUNSEL & SECR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,591 Underlying: Performance Share Units · 15,591 shares Expires not disclosed F4 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 15,591 shares will be issued. The actual number of shares to be issued could range from a low of 3,118 at minimum performance to a high of 31,182 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F6 · derivative.exercise_date: Vests on August 2, 2024. F6 · derivative.expiration_date: Vests on August 2, 2024. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 18:25 UTC |
Fong Ivan KEVP GENERAL COUNSEL & SECR
|
GrantStock Option (Right to Buy) · Derivative | 50,476 | $103.59 Strike: $103.59 | $5,228,808.84 |
DisclosureSEC source: 0001127602-22-003243 · form4.xml · derivative · entry 3 Fong Ivan K · CIK 0001342238 · EVP GENERAL COUNSEL & SECR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,476 Underlying: Ordinary Shares · 50,476 shares Expires 2031-08-02 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the date noted. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 18:25 UTC |
Fong Ivan KEVP GENERAL COUNSEL & SECR
|
GrantOrdinary Shares | 24,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003243 · form4.xml · nonDerivative · entry 2 Fong Ivan K · CIK 0001342238 · EVP GENERAL COUNSEL & SECR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,371 F2 · kind: The restrictions on these restricted stock units shall vest 50% on December 10, 2022, 25% on December 10, 2023 and 25% on December 10, 2024. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 18:25 UTC |
Fong Ivan KEVP GENERAL COUNSEL & SECR
|
GrantOrdinary Shares | 6,237 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003243 · form4.xml · nonDerivative · entry 1 Fong Ivan K · CIK 0001342238 · EVP GENERAL COUNSEL & SECR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,237 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on August 2, 2024. Read SEC document |
| December 23, 2021 Filed Dec 27, 2021 18:31 UTC |
WHITE ROBERT JOHNEVP & Pres. Medical Surgical
|
SaleOrdinary Shares | 7,218 | $102.04 | $736,524.72 |
DisclosureSEC source: 0001127602-21-031951 · form4.xml · nonDerivative · entry 1 WHITE ROBERT JOHN · CIK 0001726709 · EVP & Pres. Medical Surgical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,430 Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 21:57 UTC |
ANDERSON RICHARD HDirector
|
PurchaseOrdinary Shares | 5,010 | $103.26 | $517,332.60 |
DisclosureSEC source: 0001127602-21-031417 · form4.xml · nonDerivative · entry 1 ANDERSON RICHARD H · CIK 0001200334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,374 F1 · price: The price reported is a weighted average price. Shares were purchased in multiple transactions at prices ranging from $103.26 to $103.50. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, full information regarding the number of shares purchased at each price. F2 · balance_after: This balance increased by 314 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 23:31 UTC |
Salmon SeanEVP & Pres Diabetes/Cardiovasc
|
Tax withholdingOrdinary Shares | 89 | $104.94 | $9,339.66 |
DisclosureSEC source: 0001127602-21-031183 · form4.xml · nonDerivative · entry 1 Salmon Sean · CIK 0001792380 · EVP & Pres Diabetes/Cardiovasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,083 F1 · balance_after: The reported transaction involved the withholding of 89 shares of stock issuable upon the early vesting of an equal number of restricted stock units to pay taxes associated with the reporting person becoming retirement eligible. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 23:23 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
SaleOrdinary Shares | 682 | $110.00 | $75,020.00 |
DisclosureSEC source: 0001127602-21-030500 · form4.xml · nonDerivative · entry 3 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,446 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · balance_after: This balance increased by 154 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 23:23 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GiftOrdinary Shares | 49,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-030500 · form4.xml · nonDerivative · entry 2 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Jeffrey S. Parkhill 2021 Irrevocable Trust Disclosed balance after: 49,859 F1 · ownership.nature: These shares are held in the Jeffrey S. Parkhill 2021 Irrevocable Trust, of which the insider is the trustee and a beneficiary. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 23:23 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GiftOrdinary Shares | 49,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-030500 · form4.xml · nonDerivative · entry 1 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Parkhill Family Trust Disclosed balance after: 0 Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 18:03 UTC |
Liddicoat John REVP & President of Americas
|
Tax withholdingOrdinary Shares | 139 | $122.98 | $17,094.22 |
DisclosureSEC source: 0001127602-21-028741 · form4.xml · nonDerivative · entry 1 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,998 F1 · balance_after: The reported transaction involved the withholding of 139 shares of stock issuable upon the early vesting of an equal number of restricted stock units to pay taxes associated with the reporting person becoming retirement eligible. F2 · balance_after: This balance increased by 290 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 18:08 UTC |
WHITE ROBERT JOHNEVP & Pres. Medical Surgical
|
Tax withholdingOrdinary Shares | 246 | $122.98 | $30,253.08 |
DisclosureSEC source: 0001127602-21-028744 · form4.xml · nonDerivative · entry 1 WHITE ROBERT JOHN · CIK 0001726709 · EVP & Pres. Medical Surgical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,648 F1 · balance_after: The reported transaction involved the withholding of 246 shares of stock issuable upon the early vesting of an equal number of restricted stock units to pay taxes associated with the reporting person becoming retirement eligible. F2 · balance_after: This balance increased by 125 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 23:06 UTC |
Wall Brett A.EVP & Pres Neuroscience
|
Tax withholdingOrdinary Shares | 238 | $122.98 | $29,269.24 |
DisclosureSEC source: 0001127602-21-028743 · form4.xml · nonDerivative · entry 1 Wall Brett A. · CIK 0001473812 · EVP & Pres Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,251 F1 · balance_after: The reported transaction involved the withholding of 238 shares of stock issuable upon the early vesting of an equal number of restricted stock units to pay taxes associated with the reporting person becoming retirement eligible. F2 · balance_after: This balance increased by 94 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 22:58 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
Tax withholdingOrdinary Shares | 209 | $122.98 | $25,702.82 |
DisclosureSEC source: 0001127602-21-028739 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,945 F1 · balance_after: This balance increased by 239 shares due to exempt transactions such as dividend reinvestment. F2 · balance_after: The reported transaction involved the withholding of 209 shares of stock issuable upon the early vesting of an equal number of restricted stock units to pay taxes associated with the reporting person becoming retirement eligible. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 23:01 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
Tax withholdingOrdinary Shares | 250 | $122.98 | $30,745.00 |
DisclosureSEC source: 0001127602-21-028740 · form4.xml · nonDerivative · entry 1 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,635 F1 · balance_after: This balance increased by 122 shares due to exempt transactions such as dividend reinvestment. F2 · balance_after: The reported transaction involved the withholding of 250 shares of stock issuable upon the early vesting of an equal number of restricted stock units to pay taxes associated with the reporting person becoming retirement eligible. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 23:05 UTC |
Salmon SeanEVP & Pres Diabetes/Cardiovasc
|
Tax withholdingOrdinary Shares | 245 | $122.98 | $30,130.10 |
DisclosureSEC source: 0001127602-21-028742 · form4.xml · nonDerivative · entry 1 Salmon Sean · CIK 0001792380 · EVP & Pres Diabetes/Cardiovasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,172 F1 · balance_after: The reported transaction involved the withholding of 245 shares of stock issuable upon the early vesting of an equal number of restricted stock units to pay taxes associated with the reporting person becoming retirement eligible. F2 · balance_after: This balance increased by 88 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 17:50 UTC |
TEN HOEDT ROBEVP & President EMEA
|
GrantPerformance Share Units · Derivative | 2,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-028352 · form4.xml · derivative · entry 3 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,080 Underlying: Performance Share Units · 2,080 shares Expires not disclosed F4 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 2,080 shares will be issued. The actual number of shares to be issued could range from a low of 0 shares at minimum performance to a high of 4,160 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F6 · derivative.exercise_date: Vests on August 2, 2024. F6 · derivative.expiration_date: Vests on August 2, 2024. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 17:50 UTC |
TEN HOEDT ROBEVP & President EMEA
|
GrantStock Option (Right to Buy) · Derivative | 6,670 | $0.00 Strike: $120.23 | $0.00 |
DisclosureSEC source: 0001127602-21-028352 · form4.xml · derivative · entry 2 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,670 Underlying: Ordinary Shares · 6,670 shares Expires 2031-08-02 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the date noted. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 17:50 UTC |
TEN HOEDT ROBEVP & President EMEA
|
GrantOrdinary Shares | 832 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-028352 · form4.xml · nonDerivative · entry 1 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,418 F1 · kind: The restrictions on the award shall lapse 100% on August 2, 2024. F2 · balance_after: This balance increased by 97 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| October 08, 2021 Filed Oct 14, 2021 21:41 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GiftOrdinary Shares | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-027091 · form4.xml · nonDerivative · entry 4 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Parkhill Family Trust Disclosed balance after: 49,859 F1 · ownership.nature: These shares are held in the Parkhill Family Trust, of which the insider is a trustee with her spouse and also a beneficiary with her children. Read SEC document |
| October 08, 2021 Filed Oct 14, 2021 21:41 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GiftOrdinary Shares | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-027091 · form4.xml · nonDerivative · entry 3 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,974 Read SEC document |
| October 06, 2021 Filed Oct 14, 2021 21:41 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GiftOrdinary Shares | 37,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-027091 · form4.xml · nonDerivative · entry 2 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Parkhill Family Trust Disclosed balance after: 37,859 F1 · ownership.nature: These shares are held in the Parkhill Family Trust, of which the insider is a trustee with her spouse and also a beneficiary with her children. Read SEC document |
| October 06, 2021 Filed Oct 14, 2021 21:41 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GiftOrdinary Shares | 37,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-027091 · form4.xml · nonDerivative · entry 1 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,974 Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 22:13 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 49,147 | $0.00 Strike: $78.00 | $0.00 |
DisclosureSEC source: 0001127602-21-026351 · form4.xml · derivative · entry 3 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 49,147 shares Expires 2025-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 22:13 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
SaleOrdinary Shares | 49,147 | $126.58 | $6,221,027.26 |
DisclosureSEC source: 0001127602-21-026351 · form4.xml · nonDerivative · entry 2 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,763 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 22:13 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
Exercise / conversionOrdinary Shares | 49,147 | $78.00 | $3,833,466.00 |
DisclosureSEC source: 0001127602-21-026351 · form4.xml · nonDerivative · entry 1 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 21:27 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 50,775 | $0.00 Strike: $74.84 | $0.00 |
DisclosureSEC source: 0001127602-21-024699 · form4.xml · derivative · entry 3 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 50,775 shares Expires 2025-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: This option becomes exercisable on June 29, 2018, subject to Medtronic's achievement of a pre-specified cash Earnings Per Share Growth Rate for fiscal years 2016 through 2018. F3 · derivative.expiration_date: This date was previously reported incorrectly as 7/28/2024. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 21:27 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
SaleOrdinary Shares | 50,775 | $134.17 | $6,812,481.75 |
DisclosureSEC source: 0001127602-21-024699 · form4.xml · nonDerivative · entry 2 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,763 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 21:27 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
Exercise / conversionOrdinary Shares | 50,775 | $74.84 | $3,800,001.00 |
DisclosureSEC source: 0001127602-21-024699 · form4.xml · nonDerivative · entry 1 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 23:26 UTC |
Martha GeoffreyDirector · CEO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,100 | $0.00 Strike: $62.76 | $0.00 |
DisclosureSEC source: 0001127602-21-024366 · form4.xml · derivative · entry 6 Martha Geoffrey · CIK 0001560409 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,519 Underlying: Ordinary Shares · 10,100 shares Expires 2024-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: This option to purchase 1,594 Medtronic ordinary shares for $62.76 per share, which was unvested at the effective time of the Covidien acquisition, represents the conversion of an option to purchase 1,594 Medtronic Inc. common stock shares for $62.76 per share. This Medtronic plc stock option has the same terms and conditions as the original Medtronic Inc. stock option. F5 · derivative.exercise_date: This option to purchase 27,619 Medtronic ordinary shares for $62.76 per share, which was unvested at the effective time of the Covidien acquisition, represents the conversion of 27,619 Medtronic common stock shares for $62.76 per share. This Medtronic plc stock option has the same terms and conditions as the original Medtronic Inc. stock option. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 23:26 UTC |
Martha GeoffreyDirector · CEO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,481 | $0.00 Strike: $55.32 | $0.00 |
DisclosureSEC source: 0001127602-21-024366 · form4.xml · derivative · entry 5 Martha Geoffrey · CIK 0001560409 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,481 shares Expires 2023-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: This option to purchase 1,808 Medtronic ordinary shares for $55.32 per share, which was partially vested at the effective time of the Covidien acquisition, represents the conversion of an option to purchase 1,808 Medtronic Inc. common stock shares for $55.32 per share. This Medtronic plc stock option has the same terms and conditions as the original Medtronic Inc. stock option. F3 · derivative.exercise_date: This option to purchase 20,481 Medtronic ordinary shares for $55.32 per share, which was partially vested at the effective time of the Covidien acquisition, represents the conversion of an option to purchase 20,481 Medtronic Inc. common stock shares for $55.32 per share. This Medtronic plc stock option has the same terms and conditions as the original Medtronic Inc. stock option. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 23:26 UTC |
Martha GeoffreyDirector · CEO
|
SaleOrdinary Shares | 10,100 | $132.67 | $1,339,967.00 |
DisclosureSEC source: 0001127602-21-024366 · form4.xml · nonDerivative · entry 4 Martha Geoffrey · CIK 0001560409 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,836 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 23:26 UTC |
Martha GeoffreyDirector · CEO
|
Exercise / conversionOrdinary Shares | 10,100 | $62.76 | $633,876.00 |
DisclosureSEC source: 0001127602-21-024366 · form4.xml · nonDerivative · entry 3 Martha Geoffrey · CIK 0001560409 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 23:26 UTC |
Martha GeoffreyDirector · CEO
|
SaleOrdinary Shares | 1,481 | $132.67 | $196,484.27 |
DisclosureSEC source: 0001127602-21-024366 · form4.xml · nonDerivative · entry 2 Martha Geoffrey · CIK 0001560409 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,836 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 23:26 UTC |
Martha GeoffreyDirector · CEO
|
Exercise / conversionOrdinary Shares | 1,481 | $55.32 | $81,928.92 |
DisclosureSEC source: 0001127602-21-024366 · form4.xml · nonDerivative · entry 1 Martha Geoffrey · CIK 0001560409 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 23:28 UTC |
Salmon SeanEVP & Pres Diabetes/Cardiovasc
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,713 | $0.00 Strike: $38.20 | $0.00 |
DisclosureSEC source: 0001127602-21-024367 · form4.xml · derivative · entry 8 Salmon Sean · CIK 0001792380 · EVP & Pres Diabetes/Cardiovasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,713 shares Expires 2022-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of the grant. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 23:28 UTC |
Salmon SeanEVP & Pres Diabetes/Cardiovasc
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,577 | $0.00 Strike: $38.81 | $0.00 |
DisclosureSEC source: 0001127602-21-024367 · form4.xml · derivative · entry 7 Salmon Sean · CIK 0001792380 · EVP & Pres Diabetes/Cardiovasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,577 shares Expires 2022-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of the grant. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 23:28 UTC |
Salmon SeanEVP & Pres Diabetes/Cardiovasc
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 21,129 | $0.00 Strike: $38.81 | $0.00 |
DisclosureSEC source: 0001127602-21-024367 · form4.xml · derivative · entry 6 Salmon Sean · CIK 0001792380 · EVP & Pres Diabetes/Cardiovasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 21,129 shares Expires 2022-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of the grant. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 23:28 UTC |
Salmon SeanEVP & Pres Diabetes/Cardiovasc
|
SaleOrdinary Shares | 7,290 | $134.09 | $977,516.10 |
DisclosureSEC source: 0001127602-21-024367 · form4.xml · nonDerivative · entry 5 Salmon Sean · CIK 0001792380 · EVP & Pres Diabetes/Cardiovasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,329 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.